# General Marble (Greece)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/general-marble-greece/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 82.3 |
| Citations | 513 |
| City | Cholargós |
| Country | GR |
| Description | General Marble (Greece) is a research organisation in Cholargós, GR. OpenAlex records 75 works and 513 citations for it. 188 researchers list it as their most recent affiliation. |
| OpenAlex ID | https://openalex.org/I4210162241 |
| Researchers | 188 |
| ROR ID | https://ror.org/058fftp70 |
| Type | company |
| Works | 75 |

## University papers

Showing 12 of 14.

- [Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/non-small-cell-lung-cancer-version-3-2022-nccn-clinical-practice-guidelines-in/)
- [NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-2-2021/)
- [NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-1-2020/)
- [NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-4-2016/)
- [Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer](https://scholariq.org/papers/perioperative-durvalumab-for-resectable-non-small-cell-lung-cancer/)
- [Morbidity and Mortality of Major Pulmonary Resections in Patients With Early-Stage Lung Cancer: Initial Results of the Randomized, Prospective ACOSOG Z0030 Trial](https://scholariq.org/papers/morbidity-and-mortality-of-major-pulmonary-resections-in-patients-with-early/)
- [A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo](https://scholariq.org/papers/a-dll3-targeted-antibody-drug-conjugate-eradicates-high-grade-pulmonary/)
- [Non–Small Cell Lung Cancer, Version 6.2015](https://scholariq.org/papers/non-small-cell-lung-cancer-version-6-2015/)
- [Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/small-cell-lung-cancer-version-2-2022-nccn-clinical-practice-guidelines-in/)
- [A framework for concepts of reserve and resilience in aging](https://scholariq.org/papers/a-framework-for-concepts-of-reserve-and-resilience-in-aging/)
- [Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry](https://scholariq.org/papers/impact-of-examined-lymph-node-count-on-precise-staging-and-long-term-survival-of/)
- [Bronchial carcinoid tumors: A retrospective analysis of 126 patients](https://scholariq.org/papers/bronchial-carcinoid-tumors-a-retrospective-analysis-of-126-patients/)

## University top topics

Showing 8 of 21.

- [Climate variability and models](https://scholariq.org/topics/climate-variability-and-models/)
- [E-Government and Public Services](https://scholariq.org/topics/e-government-and-public-services/)
- [Corruption and Economic Development](https://scholariq.org/topics/corruption-and-economic-development/)
- [Atmospheric and Environmental Gas Dynamics](https://scholariq.org/topics/atmospheric-and-environmental-gas-dynamics/)
- [Respiratory and Cough-Related Research](https://scholariq.org/topics/respiratory-and-cough-related-research/)
- [Image Processing and 3D Reconstruction](https://scholariq.org/topics/image-processing-and-3d-reconstruction/)
- [Obesity, Physical Activity, Diet](https://scholariq.org/topics/obesity-physical-activity-diet/)
- [Archaeology and ancient environmental studies](https://scholariq.org/topics/archaeology-and-ancient-environmental-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.